Eisai (ESAIY) and Biogen (BIIB) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has reaffirmed its positive opinion by consensus for the anti-Abeta monoclonal antibody lecanemab, adopted in November 2024. Following CHMP’s reaffirmation, after having considered the additional information requested by the European Commission, the EC will resume the decision-making process for lecanemab’s marketing authorization.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Biogen, Eisai announces CHMP of EMA reaffirmed positive opinion of lecanemab
- Stoke Therapeutics price target raised to $47 from $35 at H.C. Wainwright
- Biogen, Stoke Therapeutics announce zorevunersen commercialization agreement
- Biogen price target lowered to $135 from $138 at Piper Sandler
- QQQ ETF News, 2/17/2025